Cutaneous lesions in sporadic angiosarcomas of the breast: a misleading presentation
P. Combemale(Centre Léon Bérard), S. Dalac‐Rat(Centre Hospitalier du Mans), Jessica Hetu(Centre Léon Bérard), Anne-Marie Provensal(Centre Léon Bérard), Christine Castillo(Centre Hospitalier Universitaire de Lille), Isabelle Ray Coquard(Centre Léon Bérard), Catherine Chassagne‐Clément(Centre Léon Bérard), Marie Hélène Aubriot-Lorton(CHU Dijon Bourgogne), G. Jeudy(CHU Dijon Bourgogne)
Cited by 1
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network
|Journal of Clinical Oncology|2017|219
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192